CMRX Chimerix Inc

Price (delayed)

$6.14

Market cap

$529.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.79

Enterprise value

$520.78M

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious ...

Highlights
The equity rose by 28% year-on-year but it has declined by 11% since the previous quarter
CMRX's quick ratio has dropped by 66% year-on-year and by 19% since the previous quarter
The company's gross profit has shrunk by 60% YoY and by 18% QoQ

Key stats

What are the main financial stats of CMRX
Market
Shares outstanding
86.25M
Market cap
$529.57M
Enterprise value
$520.78M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.44
Price to sales (P/S)
116.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
114.33
Earnings
Revenue
$4.56M
EBIT
-$138.26M
EBITDA
-$137.65M
Free cash flow
-$68.19M
Per share
EPS
-$1.79
Free cash flow per share
-$0.79
Book value per share
$1.38
Revenue per share
$0.05
TBVPS
$1.7
Balance sheet
Total assets
$146.73M
Total liabilities
$27.58M
Debt
$16.65M
Equity
$119.15M
Working capital
$111.33M
Liquidity
Debt to equity
0.14
Current ratio
5.47
Quick ratio
5.3
Net debt/EBITDA
0.06
Margins
EBITDA margin
-3,022%
Gross margin
100%
Net margin
-3,035.4%
Operating margin
-3,042.5%
Efficiency
Return on assets
-114.4%
Return on equity
-135.1%
Return on invested capital
-174.5%
Return on capital employed
-113.5%
Return on sales
-3,035.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CMRX stock price

How has the Chimerix stock price performed over time
Intraday
-2.07%
1 week
-11.27%
1 month
1.49%
1 year
161.28%
YTD
27.12%
QTD
-23.25%

Financial performance

How have Chimerix's revenue and profit performed over time
Revenue
$4.56M
Gross profit
$4.56M
Operating income
-$138.59M
Net income
-$138.26M
Gross margin
100%
Net margin
-3,035.4%
The company's gross profit has shrunk by 60% YoY and by 18% QoQ
Chimerix's revenue has plunged by 60% YoY and by 18% from the previous quarter
The net income has decreased by 42% YoY and by 6% from the previous quarter
The operating income has decreased by 39% YoY and by 6% QoQ

Growth

What is Chimerix's growth rate over time

Valuation

What is Chimerix stock price valuation
P/E
N/A
P/B
4.44
P/S
116.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
114.33
The EPS has contracted by 13% YoY and by 2.9% from the previous quarter
The stock's price to book (P/B) is 147% more than its 5-year quarterly average of 1.8
The equity rose by 28% year-on-year but it has declined by 11% since the previous quarter
CMRX's P/S is 158% higher than its 5-year quarterly average of 45.1 and 29% higher than its last 4 quarters average of 90.1
Chimerix's revenue has plunged by 60% YoY and by 18% from the previous quarter

Efficiency

How efficient is Chimerix business performance
Chimerix's return on equity has decreased by 44% YoY
Chimerix's ROIC has decreased by 37% YoY but it has increased by 17% from the previous quarter
CMRX's return on assets is down by 34% year-on-year but it is up by 3.9% since the previous quarter
The ROS has contracted by 29% from the previous quarter

Dividends

What is CMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CMRX.

Financial health

How did Chimerix financials performed over time
The current ratio has dropped by 66% year-on-year and by 18% since the previous quarter
CMRX's quick ratio has dropped by 66% year-on-year and by 19% since the previous quarter
The debt is 86% less than the equity
The equity rose by 28% year-on-year but it has declined by 11% since the previous quarter
The debt to equity rose by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.